- Pancreatic enzyme supplements
- Mucolytics
- Bronchodilators
- CFTR Modulators
Cystic Fibrosis (CF) Treatment Market size was valued at USD 5040.0 million in 2021 and is expected to reach USD 9332.3 million by 2028, at a CAGR of 9.2% during the forecast period 2022-2028. Cystic fibrosis is a genetic disorder that causes severe damage to secretory glands of body such as lungs, pancreas, liver and intestines. It is more common in lungs. The disease is progressive with several mutations in the genes, which causes cystic fibrosis. In cystic fibrosis, the abnormal secretions from various secretory glands builds mucus which results in improper working of the organ that is affected. The treatment of cystic fibrosis helps loosening mucus which includes physical therapy. There are various therapeutic products available for the treatment of cystic fibrosis, which include enzymes, antibiotics and others. According to CFF’s national patient registry, the median age of the person with cystic fibrosis is currently 33.4 years. Basing on the severity of the disease, cystic fibrosis signs and symptoms vary. The Wide- research on Cystic Fibrosis (CF) resulted in dramatic improvements in the treatment of the disease, which has quadrupled the median life expectancy to 37 years of age in the U.S. In parts of the world where state-of-the-art medical care is not available, life expectancy remains much lower. In Europe, 51.8% were adults with age 18 years or more and 48.2% were less than 18 years old. New therapeutics are currently in development, of which some may provide a functional CFTR protein in patients with some versions of the gene, potentially eliminating many disease complications and allowing people with the disease to live essentially normal lives. Cystic fibrosis is a hereditary disease that mostly affects the lungs, but also affects the pancreas, liver, and kidney. The cystic fibrosis transmembrane conductance regulator (CFTR) gene mutation causes it. This gene, which is found on chromosome 7, is in charge of perspiration, mucus, and bodily fluids regulation. However, a mutation in this gene causes CFTR activity to be absent, resulting in chloride loss and protein structural changes.
Study Period
Base Year
CAGR
Largest Market
Fastest Growing Market
The major factors that are driving cystic fibrosis (CF) treatment market includes, increasing prevalence of the cystic fibrosis, rising awareness among healthcare fraternity about cystic fibrosis therapy. Advancement in the technology, and better healthcare facilities are also some of the factors influencing the cystic fibrosis therapeutics market. However, the cystic fibrosis therapeutics market growth hindering due to high cost of the treatment, increase in complexity of disease. Moreover, patent expiries from many companies and introduction of generic drugs hold back the growth of global cystic fibrosis market
2021 is the base year and 2028 is the forecast year.
The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).
In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.
Table of Content |
1. Executive Summary |
2. Global Cystic Fibrosis Treatment Market Introduction |
2.1. Global Cystic Fibrosis Treatment Market – Taxonomy |
2.2. Global Cystic Fibrosis Treatment Market –Definitions |
2.2.1. By Drug Class |
2.2.2. By Route of Administration |
2.2.3. By Region |
3. Global Cystic Fibrosis Treatment Market Dynamics |
3.1. Drivers |
3.2. Restraints |
3.3. Opportunities/Unmet Needs of the Market |
3.4. Trends |
3.5. Global Cystic Fibrosis Treatment Market Dynamic Factors - Impact Analysis |
3.6. Global Cystic Fibrosis Treatment Market – Competition Landscape |
4. Global Cystic Fibrosis Treatment Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 |
4.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn) |
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) |
4.3. Market Opportunity Analysis |
5. Global Cystic Fibrosis Treatment Market, By Drug Class, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn) |
5.1. Pancreatic enzyme supplements |
5.1.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn) |
5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.1.3. Market Opportunity Analysis |
5.2. Mucolytics |
5.2.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn) |
5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.2.3. Market Opportunity Analysis |
5.3. Bronchodilators |
5.3.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn) |
5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.3.3. Market Opportunity Analysis |
5.4. CFTR Modulators |
5.4.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn) |
5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.4.3. Market Opportunity Analysis |
6. Global Cystic Fibrosis Treatment Market, By Route of Administration, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn) |
6.1. Oral drugs |
6.1.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn) |
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.1.3. Market Opportunity Analysis |
6.2. Inhaled drugs |
6.2.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn) |
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.2.3. Market Opportunity Analysis |
7. Global Cystic Fibrosis Treatment Market Forecast, By Region, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn) |
7.1. North America |
7.1.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn) |
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.1.3. Market Opportunity Analysis |
7.2. Europe |
7.2.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn) |
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.2.3. Market Opportunity Analysis |
7.3. Asia-Pacific |
7.3.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn) |
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.3.3. Market Opportunity Analysis |
7.4. Latin America |
7.4.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn) |
7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.4.3. Market Opportunity Analysis |
7.5. Middle East and Africa |
7.5.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn) |
7.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.5.3. Market Opportunity Analysis |
7.6. Global Cystic Fibrosis Treatment Market - Opportunity Analysis Index, By Drug Class, Route of Administration, and Region, 2022 - 2028 |
8. North America Cystic Fibrosis Treatment Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn) |
8.1. Drug Class Analysis 2017 - 2021 and Forecast 2022 - 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
8.1.1. Pancreatic enzyme supplements |
8.1.2. Mucolytics |
8.1.3. Bronchodilators |
8.1.4. CFTR Modulators |
8.2. Route of Administration Analysis 2017 - 2021 and Forecast 2022 - 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
8.2.1. Oral drugs |
8.2.2. Inhaled drugs |
8.3. Country Analysis 2017 - 2021 and Forecast 2022 - 2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
8.3.1. USA |
8.3.2. Canada |
8.4. North America Cystic Fibrosis Treatment Market - Opportunity Analysis Index, By Drug Class, Route of Administration, and Country, 2022 - 2028 |
8.5. North America Cystic Fibrosis Treatment Market Dynamics – Trends |
9. Europe Cystic Fibrosis Treatment Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn) |
9.1. Drug Class Analysis 2017 - 2021 and Forecast 2022 - 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
9.1.1. Pancreatic enzyme supplements |
9.1.2. Mucolytics |
9.1.3. Bronchodilators |
9.1.4. CFTR Modulators |
9.2. Route of Administration Analysis 2017 - 2021 and Forecast 2022 - 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
9.2.1. Oral drugs |
9.2.2. Inhaled drugs |
9.3. Country Analysis 2017 - 2021 and Forecast 2022 - 2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
9.3.1. Germany |
9.3.2. UK |
9.3.3. France |
9.3.4. Spain |
9.3.5. Italy |
9.3.6. Russia |
9.3.7. Rest of Europe |
9.4. Europe Cystic Fibrosis Treatment Market - Opportunity Analysis Index, By Drug Class, Route of Administration, and Country, 2022 - 2028 |
9.5. Europe Cystic Fibrosis Treatment Market Dynamics – Trends |
10. Asia-Pacific Cystic Fibrosis Treatment Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn) |
10.1. Drug Class Analysis 2017 - 2021 and Forecast 2022 - 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
10.1.1. Pancreatic enzyme supplements |
10.1.2. Mucolytics |
10.1.3. Bronchodilators |
10.1.4. CFTR Modulators |
10.2. Route of Administration Analysis 2017 - 2021 and Forecast 2022 - 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
10.2.1. Oral drugs |
10.2.2. Inhaled drugs |
10.3. Country Analysis 2017 - 2021 and Forecast 2022 - 2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
10.3.1. China |
10.3.2. India |
10.3.3. Japan |
10.3.4. ASEAN |
10.3.5. Australia & New Zealand |
10.3.6. Rest of Asia-Pacific |
10.4. Asia-Pacific Cystic Fibrosis Treatment Market - Opportunity Analysis Index, By Drug Class, Route of Administration, and Country, 2022 - 2028 |
10.5. Asia-Pacific Cystic Fibrosis Treatment Market Dynamics – Trends |
11. Latin America Cystic Fibrosis Treatment Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn) |
11.1. Drug Class Analysis 2017 - 2021 and Forecast 2022 - 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
11.1.1. Pancreatic enzyme supplements |
11.1.2. Mucolytics |
11.1.3. Bronchodilators |
11.1.4. CFTR Modulators |
11.2. Route of Administration Analysis 2017 - 2021 and Forecast 2022 - 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
11.2.1. Oral drugs |
11.2.2. Inhaled drugs |
11.3. Country Analysis 2017 - 2021 and Forecast 2022 - 2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
11.3.1. Brazil |
11.3.2. Mexico |
11.3.3. Argentina |
11.3.4. Rest of Latin America |
11.4. Latin America Cystic Fibrosis Treatment Market - Opportunity Analysis Index, By Drug Class, Route of Administration, and Country, 2022 - 2028 |
11.5. Latin America Cystic Fibrosis Treatment Market Dynamics – Trends |
12. Middle East and Africa Cystic Fibrosis Treatment Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn) |
12.1. Drug Class Analysis 2017 - 2021 and Forecast 2022 - 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
12.1.1. Pancreatic enzyme supplements |
12.1.2. Mucolytics |
12.1.3. Bronchodilators |
12.1.4. CFTR Modulators |
12.2. Route of Administration Analysis 2017 - 2021 and Forecast 2022 - 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
12.2.1. Oral drugs |
12.2.2. Inhaled drugs |
12.3. Country Analysis 2017 - 2021 and Forecast 2022 - 2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
12.3.1. Gulf Cooperation Council (GCC) Countries |
12.3.2. Israel |
12.3.3. South Africa |
12.3.4. Rest of MEA |
12.4. MEA Cystic Fibrosis Treatment Market - Opportunity Analysis Index, By Drug Class, Route of Administration, and Country, 2022 - 2028 |
12.5. MEA Cystic Fibrosis Treatment Market Dynamics – Trends |
13. Competition Landscape |
13.1. Strategic Dashboard of Top Market Players |
13.2. Company Profiles (Introduction, Financial Analysis, Drug Class Offerings, Key Developments, Strategies, and SWOT Analysis) |
13.2.1. Abbvie Inc. |
13.2.2. Alaxia |
13.2.3. Allergan |
13.2.4. Alcresta Therapeutics Inc. |
13.2.5. AstraZeneca |
13.2.6. F. Hoffmann-La Roche Ltd |
13.2.7. Gilead Sciences Inc. |
13.2.8. Merck & Co., Inc. |
13.2.9. Novartis AG |
13.2.10. Teva Pharmaceutical Industries Ltd. |
13.2.11. Vertex Pharmaceuticals Inc. |
13.2.12. Chiesi Farmaceutici SpA |
14. Research Methodology |
15. Key Assumptions and Acronyms |